Generic Name and Formulations:
Fluphenazine HCl 1mg, 2.5mg, 5mg+, 10mg; tabs; +contains tartrazine.
Various generic manufacturers
Indications for Fluphenazine:
Initially: 2.5–10mg daily in 3–4 divided doses; max 40mg daily.
Initially 1–2.5mg daily in 3–4 divided doses; max 40mg daily.
Coma. CNS or bone marrow depression. Liver disease. Subcortical brain damage. Blood dyscrasias.
Cardiovascular or renal disease. Pheochromocytoma. Seizures. Glaucoma. History of breast cancer. Exposure to extreme heat or organophosphates. Gradually reduce to lowest effective maintenance dose. Monitor blood, liver, renal, and ocular function. Mental retardation. Surgery. Pregnancy. Nursing mothers.
Potentiates anticholinergics, CNS depression with alcohol and other CNS depressants; both drugs with propranolol. Antagonized by anticholinergics. Decreased guanethidine effects. May cause false (+) pregnancy test.
Drowsiness, anticholinergic and other autonomic effects, insomnia, restlessness, rash, photosensitivity, tardive dyskinesia, blood dyscrasias, jaundice, pneumonia, hypertension, retinopathy, lowered seizure threshold, extrapyramidal reactions, neuroleptic malignant syndrome, weight changes, endocrine effects.
Formerly known under the brand names Prolixin (tabs, concentrate, elixir, inj); Permitil (tabs, concentrate); Prolixin Decanoate (decanoate inj).
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking